Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study has two main aims. The first is to assess whether Dexamethasone can increase the
number of patients with who respond to Velcade.
The second aim of this study is to see whether treating patients with relapsed multiple
myeloma with Velcade and Dexamethasone for a longer period of time extends the time that the
myeloma is under control.